多发性骨髓瘤患者血清IL-10、IL-12和sFas水平及其临床意义

目的 研究多发性骨髓瘤(MM)患者血清白细胞介素10(IL-10)、白细胞介素12(IL-12)和可溶性Fas(sFas)水平及其在MM发病机制中的作用.方法 采用酶联免疫夹心(ELISA)法检测15例MM患者和20例正常人血清IL-10、IL-12和sFas水平.结果 与正常组比较,MM患者IL-10和sFas水平明显升高(P＜0.01);IL-12水平有下降趋势,但无显著性差异(p＞0.05).结论 IL-10、IL-12和sFas参与MM的免疫病理生理过程.检测上述三种细胞因子水平变化,为MM患者监测病情、疗效判断及免疫治疗提供较为客观指标.

Determination and Clinical significance of Serum Levels of IL-10,IL-12 and sFas in Patients with Multiple Myeloma

Objective To study the serum levels of interleukin 10(IL-10),interleukin 12(IL-12),soluble Fas(sFas) in patients with multiple myeloma(MM),and to explore their functions in the immune pathogenesis of MM. Methods Enzyme linked immunosorbent assay(ELISA) was used to detect IL-10,IL-12 and sFas in serums of 15 patients with MM and 20 normal controls. Results The serum levels of IL-10 and sFas were significantly higher in patients with MM than those in controls(P<0.01). And the levels of IL-12 in MM patients tended to decrease,but there was no significant difference between the MM patients and the controls(P>0.05) Conclusion IL-10,IL-12 and sFas all participate in the immune pathophysiological progress of MM.The combined detection of IL-10,IL-12 and sFas may offer valuable parameter to monitor the disease progress and to evaluate the immune treatment and curative effect in patients with MM.